stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Return on equity
Genmab A/S Sponsored ADR's return on equity over the twelve months to 30 June 2026 was 14.0%, down 3.5 percentage points from fiscal 2025 (17.5%). Over the past ten years it has ranged from 14.8% (fiscal 2021) to 29.0% (fiscal 2020); the current reading is higher than 30% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 17.5% | (5.77) |
| FY2024 | 23.3% | 8.39 |
| FY2023 | 14.9% | (6.17) |
| FY2022 | 21.1% | 6.27 |
| FY2021 | 14.8% | (14.14) |
| FY2020 | 29.0% | 9.71 |
| FY2019 | 19.2% | (1.22) |
| FY2018 | 20.5% | (0.52) |
| FY2017 | 21.0% | 1.11 |
| FY2016 | 19.9% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 138.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 18.4% |
| GMAB Genmab A/S Sponsored ADR | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| RVMD Revolution Medicines, Inc. compare | −93.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement